Login to Your Account

Synairgen Seeking Partner on Phase II Data for Asthma Drug

By Nuala Moran
Staff Writer

Wednesday, April 25, 2012
LONDON – Synairgen plc delivered positive data in a Phase II trial of SGN001, a therapy intended to protect asthmatics from the serious worsening of symptoms that can occur when they catch colds or other respiratory virus infections, and is now prospecting for a commercial partner.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription